These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 35138160)

  • 1. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
    Mondal T; Shivange G; Habieb A; Tushir-Singh J
    Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: Effects on proteolytic cleavage and ACE2 binding.
    Spelios MG; Capanelli JM; Li AW
    Immunol Lett; 2022 Feb; 242():1-7. PubMed ID: 35007661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Spike Furin Cleavage Site and S2' Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner.
    Lavie M; Dubuisson J; Belouzard S
    J Virol; 2022 Jul; 96(13):e0047422. PubMed ID: 35678602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.
    Sasaki M; Toba S; Itakura Y; Chambaro HM; Kishimoto M; Tabata K; Intaruck K; Uemura K; Sanaki T; Sato A; Hall WW; Orba Y; Sawa H
    mBio; 2021 Aug; 12(4):e0141521. PubMed ID: 34425707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition.
    Navaratnarajah CK; Pease DR; Halfmann PJ; Taye B; Barkhymer A; Howell KG; Charlesworth JE; Christensen TA; Kawaoka Y; Cattaneo R; Schneider JW;
    J Virol; 2021 Nov; 95(24):e0136821. PubMed ID: 34613786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide bioinformatics analysis of human protease capacity for proteolytic cleavage of the SARS-CoV-2 spike glycoprotein.
    Matveev EV; Ponomarev GV; Kazanov MD
    Microbiol Spectr; 2024 Feb; 12(2):e0353023. PubMed ID: 38189333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling.
    Frolova EI; Palchevska O; Lukash T; Dominguez F; Britt W; Frolov I
    J Virol; 2022 Aug; 96(15):e0075322. PubMed ID: 35876526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
    Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
    Elife; 2020 Oct; 9():. PubMed ID: 33103998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis.
    Johnson BA; Xie X; Bailey AL; Kalveram B; Lokugamage KG; Muruato A; Zou J; Zhang X; Juelich T; Smith JK; Zhang L; Bopp N; Schindewolf C; Vu M; Vanderheiden A; Winkler ES; Swetnam D; Plante JA; Aguilar P; Plante KS; Popov V; Lee B; Weaver SC; Suthar MS; Routh AL; Ren P; Ku Z; An Z; Debbink K; Diamond MS; Shi PY; Freiberg AN; Menachery VD
    Nature; 2021 Mar; 591(7849):293-299. PubMed ID: 33494095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2.
    Winstone H; Lista MJ; Reid AC; Bouton C; Pickering S; Galao RP; Kerridge C; Doores KJ; Swanson CM; Neil SJD
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33563656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil.
    Naveca FG; Nascimento V; Souza V; Corado AL; Nascimento F; Silva G; Mejía MC; Brandão MJ; Costa Á; Duarte D; Pessoa K; Jesus M; Gonçalves L; Fernandes C; Mattos T; Abdalla L; Santos JH; Martins A; Chui FM; Val FF; de Melo GC; Xavier MS; Sampaio VS; Mourão MP; Lacerda MV; Batista ÉLR; Magalhães ALÁ; Dábilla N; Pereira LCG; Vinhal F; Miyajima F; Dias FBS; Dos Santos ER; Coêlho D; Ferraz M; Lins R; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Resende PC; Bello G;
    Microbiol Spectr; 2022 Feb; 10(1):e0236621. PubMed ID: 35196783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin.
    Tang T; Jaimes JA; Bidon MK; Straus MR; Daniel S; Whittaker GR
    ACS Infect Dis; 2021 Feb; 7(2):264-272. PubMed ID: 33432808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets.
    Peacock TP; Goldhill DH; Zhou J; Baillon L; Frise R; Swann OC; Kugathasan R; Penn R; Brown JC; Sanchez-David RY; Braga L; Williamson MK; Hassard JA; Staller E; Hanley B; Osborn M; Giacca M; Davidson AD; Matthews DA; Barclay WS
    Nat Microbiol; 2021 Jul; 6(7):899-909. PubMed ID: 33907312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.
    Yamamoto M; Gohda J; Kobayashi A; Tomita K; Hirayama Y; Koshikawa N; Seiki M; Semba K; Akiyama T; Kawaguchi Y; Inoue JI
    mBio; 2022 Aug; 13(4):e0051922. PubMed ID: 35708281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.
    Klimstra WB; Tilston-Lunel NL; Nambulli S; Boslett J; McMillen CM; Gilliland T; Dunn MD; Sun C; Wheeler SE; Wells A; Hartman AL; McElroy AK; Reed DS; Rennick LJ; Duprex WP
    J Gen Virol; 2020 Nov; 101(11):1156-1169. PubMed ID: 32821033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve
    Shiliaev N; Lukash T; Palchevska O; Crossman DK; Green TJ; Crowley MR; Frolova EI; Frolov I
    J Virol; 2021 Oct; 95(21):e0135721. PubMed ID: 34406867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V.
    Bollavaram K; Leeman TH; Lee MW; Kulkarni A; Upshaw SG; Yang J; Song H; Platt MO
    Protein Sci; 2021 Jun; 30(6):1131-1143. PubMed ID: 33786919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.